MariTide (Maridebart Cafraglutide) 2026: Amgen's Once-Monthly GLP-1/GIP Antagonist — Phase 2 Data & Phase 3 Status

MariTide takes the opposite approach to tirzepatide: GLP-1 agonism plus GIP antagonism, delivered monthly via an antibody-peptide conjugate. Here's the Phase 2 NEJM data, safety profile, and where Amgen's Phase 3 MARITIME program stands in 2026.